Fabrication and efficacy assessment of combination of brimonidine and ivermectin for treatment of papulopustular rosacea
Journal of Cosmetic Dermatology · 2024
DOI: 10.1111/jocd.16372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Samin Fallah Pakdaman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran. Hauptthemen laut MEDLINE: Rosacea, Brimonidine Tartrate, Ivermectin, Drug Combinations. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Medical Research Development.
Abstract (Originalsprache)
Background & Aim Rosacea is a chronic inflammatory, multifactorial disease for which combination therapy could be an effective treatment. In this study, we evaluate the effect of the combination therapy of brimonidine 0.33% and ivermectin 1% as a single cream for the treatment of papulopustular rosacea.
Method
A stable and appropriate formulation was prepared by adding the aqueous phase to the lipid phase while being stirred. The stability and physicochemical properties of the formulation were evaluated under accelerated conditions. Twelve patients (36–60 years) with mild to moderate papulopustular rosacea and a Demodex count of five or more were treated with the combination of brimonidine 0.33% and ivermectin 1% cream. Clinician's Erythema Assessment (CEA), Patients Self‐Assessment (PSA), skin erythema (ΔE) and lightness (ΔL), and skin biophysical parameters including transepidermal water loss (TEWL), skin hydration, pH, and sebum content, as well as erythema and melanin index and ultrasound parameters, were measured before treatment and 4 and 8 weeks after. Adverse drug reactions were also recorded.
Results
CEA and PSA decreased significantly from 3 to 2 after 8 weeks, respectively ( p ‐value = 0.014 for CEA and 0.010 for PSA). ΔE and ΔL, as well as skin erythema index and TEWL improved after 8 weeks of treatment ( p < 0.05). Two patients withdrew from the study in the first week because of local adverse effects; one developed flushing following treatment and left the investigation after 4 weeks and another patient withdrew from the study after 4 weeks due to deciding to become pregnant.
Conclusion
Eight‐week treatment with the combination of brimonidine 0.33% and ivermectin 1% was shown to be effective for improvement of erythema and inflammatory lesions in mild to moderate papulopustular rosacea.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran.
- Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Shahid Beheshti University of Medical Science, Tehran, Iran.
ORCID-Profile: Samin Fallah Pakdaman, Aniseh Samadi, Mahsa Fattahi, Atefeh Naeimifar, Fatemeh Amiri Ardehali, Yasaman Ketabi, Saman Ahmad Nasrollahi, Alireza Firooz
Förderung
- National Institute for Medical Research Development
Zitieren
APA
Pakdaman, S. F., Samadi, A., Fattahi, M., Naeimifar, A., Ardehali, F. A., Ketabi, Y., Nasrollahi, S. A., & Firooz, A. (2024). Fabrication and efficacy assessment of combination of brimonidine and ivermectin for treatment of papulopustular rosacea. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16372
Vancouver
Pakdaman SF, Samadi A, Fattahi M, Naeimifar A, Ardehali FA, Ketabi Y, et al. Fabrication and efficacy assessment of combination of brimonidine and ivermectin for treatment of papulopustular rosacea. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16372
BibTeX
@article{Pakdaman2024,
author = {Pakdaman, Samin Fallah and Samadi, Aniseh and Fattahi, Mahsa and Naeimifar, Atefeh and Ardehali, Fatemeh Amiri and Ketabi, Yasaman and Nasrollahi, Saman Ahmad and Firooz, Alireza},
title = {Fabrication and efficacy assessment of combination of brimonidine and ivermectin for treatment of papulopustular rosacea},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
doi = {10.1111/jocd.16372}
}
EUVIMED